Significantly increases drug delivery into liver tumors
WESTMINSTER, CO—September 25, 2015 – Surefire Medical, Inc. today announced the launch of the company’s new Precision targeted delivery infusion system for direct-to-tumor embolization procedures. The new technology will be displayed at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2015 Scientific Meeting in Lisbon, Portugal, September 26-30, 2015. Surefire infusion systems are used by interventional, radiologists and interventional oncologists in minimally invasive primary and secondary liver cancer treatments.
“Chemo- and radioembolization techniques are becoming valuable treatment options in selected patients with unresectable liver tumors. The Precision catheter provides us with a new interventional tool to safely and effectively deliver drug eluting and yttrium-90 microspheres within the tumor,” said Prof. Dr. G. Maleux, Department of Radiology of the University Hospitals Leuven, Belgium.
The Precision addresses a clear need in the ability to treat primary liver cancers, 80 percent of which are inoperable, and may help lower the overall costs of treatment. A recent prospective clinical trial shows the Surefire infusion technology increased drug delivery into tumors by as much as 90 percent and reduced non-target delivery to healthy tissue. The Precision has received the CE Mark and FDA clearance.
“The drug delivery system matters far more than previously thought,” said Surefire Medical’s President and CEO James E. Chomas. “Primary liver cancers often contain regions of high pressure and no blood flow, creating a barrier to drug delivery. The Surefire Precision device uniquely overcomes this obstacle by controlling pressure during drug delivery such that drug penetration into tumors increases significantly.”
Innovative Precision Embolics Delivery System: Other Key Features
- Revolutionary Surefire Expandable Tip to achieve effective Pressure Control
- Ultra-thin catheter construction and lubricious hydrophilic coating allows the device to track as well or better than traditional microcatheters, providing access to a wide-range of vessel sizes and complex anatomies
- Compatibility with up to 500 μm beads to enable treatment of various disease types
Liver cancer is the third most common cause of cancer deaths worldwide. Hepatocellular carcinoma accounts for 83 percent of liver cancers and has an increased incidence in patients with cirrhosis or chronic inflammation such as that seen in viral hepatitis. HCC incidence has doubled in the past 20 years, increasing the cost burden of treatment.
About Surefire Medical
Surefire Medical, Inc., based in Westminster, Colo., was founded in 2009 to develop innovative infusion systems for the interventional radiology and interventional oncology markets. Surefire’s infusion systems are designed to precisely deliver embolic agents through a unique microcatheter with an expandable tip, which collapses in forward flow and dynamically expands to the vessel wall in reverse flow. Recent clinical studies suggest that the resulting pressure gradient changes preferentially shunt particles into the tumor compartment, increasing uptake by the tumor but not by normal liver tissue. For clinical trial results, and more information please visit www.surefiremedical.com.
Surefire Precision Infusion System
The new Surefire Precision infusion system has received FDA clearance and the CE Mark. Surefire Medical’s infusion systems are clinically proven to increase drug delivery into tumors by as much as 90 percent while significantly reducing non-target delivery in minimally invasive chemoembolization and radioembolization procedures to treat primary and secondary liver cancers.